ROYAL BANK OF CANADA - AMYLYX PHARMACEUTICALS INC ownership

AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 152 filers reported holding AMYLYX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of AMYLYX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$148,000
+68.2%
8,095
+98.7%
0.00%
Q2 2023$88,000
-17.8%
4,074
+12.3%
0.00%
Q1 2023$107,000
-56.7%
3,628
-45.7%
0.00%
Q4 2022$247,000
+550.0%
6,677
+386.3%
0.00%
Q3 2022$38,000
+100.0%
1,373
+36.2%
0.00%
Q2 2022$19,000
-66.1%
1,008
-76.5%
0.00%
Q1 2022$56,0004,2940.00%
Other shareholders
AMYLYX PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Alpha Wave Global, LP 930,337$27,296,08810.08%
Perceptive Advisors 6,034,644$177,056,4555.23%
GREAT POINT PARTNERS LLC 783,795$22,996,5454.52%
Ghost Tree Capital, LLC 475,000$13,937,0004.12%
Altium Capital Management LP 185,000$5,427,9003.01%
Boxer Capital, LLC 2,084,000$61,1453.00%
EMERALD MUTUAL FUND ADVISERS TRUST 789,591$23,166,6001.37%
EMERALD ADVISERS, LLC 972,835$28,542,9791.37%
SECTORAL ASSET MANAGEMENT INC 242,400$7,112,0161.37%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 1,984,333$58,220,3301.30%
View complete list of AMYLYX PHARMACEUTICALS INC shareholders